MetaCap

AbCellera Biologics (ABCL) vs Dyne Therapeutics (DYN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 176.1% versus a loss of 26.8%. Over five years, DYN leads with a +5.4% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $2.90 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%DYN-26.82%
+340%+145%-50%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%DYN-1.84%
+209%+54%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus DYN key metrics
MetricABCLDYN
Share price$9.69$15.50
Market cap$3.16B$2.90B
1-day change-7.45%-3.31%
YTD return+183.33%-20.76%
1-year return+176.07%-26.82%
5-year return-30.74%+5.37%
EPS (TTM)$-0.48$-3.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M—
Revenue growth (YoY)+160.56%—
Net income (latest FY)$-146.41M$-446.21M
Operating margin-288.98%—
Net margin-194.88%—
52-week high$15.02$27.31
52-week low$2.75$14.00
Distance from 52-week high-35.46%-43.23%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+121.48%
Average volume4.34M2.94M
Shares outstanding326.62M187.39M
Employees562322
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed DYN by 202.9 percentage points over the past year.

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

ABCL vs DYN FAQ

Which is bigger, AbCellera Biologics or Dyne Therapeutics?

AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $2.90B for Dyne Therapeutics (DYN).

Which stock has performed better over the past year, ABCL or DYN?

ABCL returned +176.07% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Dyne Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons